Drug Discovery for Schizophrenia
From Pns to CNS and Back
RSC Publishing
ISBN 978-1-83767-205-9
Standardpreis
Bibliografische Daten
Buch. Hardcover
2024
In englischer Sprache
Umfang: 264 S.
Format (B x L): 16 x 23.6 cm
Gewicht: 544
Verlag: RSC Publishing
ISBN: 978-1-83767-205-9
Produktbeschreibung
In this context, this second volume presents current evidence that views schizophrenia as a mild abnormal maldevelopment of the entire body. This includes impaired functioning of sensory systems (e.g. olfaction), and changes in blood biochemistry and the autonomic nervous system (e.g. vagal body-to-brain communication). Alternative approaches to prevent and treat schizophrenia involve advanced techniques such as opto- and chemo-genetics, as well as local administration of compounds (e.g. intranasally) targeting PNS-based cellular and molecular pathways. Chapters focus on the genetics of schizophrenia, leveraging technological advancements in high-throughput genomics and computational biology. These tools help identify novel therapeutic targets and enable the safe repurposing of existing medications.
The book emphasizes the need to develop new strategies for creating more suitable animal models of schizophrenia, considering the crucial role of the PNS in the disorder’s aetiology. While PNS-based mechanisms are often overlooked, discussing them with caution is essential. Systematically accumulating knowledge about PNS-CNS pathological mechanisms will benefit psychiatric neuroscience, offering fresh perspectives for drug discovery.
Overall, the book synthesizes expert opinions from academia and clinical studies, covering progress in genetics/pharmacogenetics, molecular and cellular neuroscience, neurobiology, pharmacology and animal models.
Autorinnen und Autoren
Produktsicherheit
Hersteller
Libri GmbH
Europaallee 1
36244 Bad Hersfeld, DE
gpsr@libri.de